Skip to main content
U.S. flag

An official website of the United States government

Return to Search

Transcatheter Mitral Valve Repair

Guidance for a Medicare National Coverage Determination which allows for coverage of TMVR under Coverage with Evidence Development (CED) with certain conditions.

Final

Issued by: Centers for Medicare & Medicaid Services (CMS)

Issue Date: January 30, 2020

Transcatheter Edge-to-Edge Repair (TEER) of the mitral valve is used in the treatment of mitral regurgitation. TEER approximates the anterior and posterior mitral valve leaflets by grasping them with a clipping device in an approach similar to a treatment developed in cardiac surgery called the Alfieri stich.

CMS issued a Medicare National Coverage Determination (NCD) on August 7, 2014 which covered transcatheter mitral valve repair (TMVR) under Coverage with Evidence Development (CED) with certain conditions. On January 19, 2021, CMS expanded coverage under CED and renamed the NCD to TEER for Mitral Valve Regurgitation to more precisely define the treatment addressed in this NCD. The complete NCD decision memos are available on our website (see links below). Under the CED criteria, CMS must approve any registry of clinical studies. Any CMS approved registry or CMS approved clinical study is listed below.

 

 

2014 TMVR Final Decision Memorandum: https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=273&bc=AAgAAAAACAAA&

2021 TEER for Mitral Valve Regurgitation Final Decision Memorandum: https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=297&bc=AAgAAAAACAAA&

 

Registry Approvals:

STS/ACC TVT Registry Mitral Module (TMVR)
Sponsor: American College of Cardiology
ClinicalTrials.gov Number:  NCT02245763
CMS Approval Date: 08/07/2014

Clinical Study Approvals:

Study Title: Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥65 Year-olds (PRIMARY)
Sponsor: Cardiothoracic Surgical Trials Network
Clinicaltrials.gov number: NCT05051033
Investigational Device Exemption (IDE) Number: G210214
CMS Approval Date: 01/04/2022

Study Title: Percutaneous MitraClipTM Device or Surgical Mitral Valve REpair in PAtients with PrImaRy MItral Regurgitation who are Candidates for Surgery (REPAIR-MR)  
Sponsor: Abbott
ClinicalTrials.gov Number: NCT04198870 
Investigational Device Exemption (IDE) Number: G190212
CMS Approval Date: 07/17/2020

Study Title: Edwards PASCAL TrAnScatheter Mitral Valve RePair System Pivotal Clinical Trial (CLASP IID) Pivotal Trial
Sponsor: Edwards Lifesciences
ClinicalTrials.gov Number: NCT03706833
Investigational Device Exemption (IDE) Number: G170166
CMS Approval Date: 11/19/2018

Study Title:  Cardiovascular Outcomes Assessment of the MitraClip® Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (the COAPT trial)
Sponsor:  Abbott Vascular
ClinicalTrials.gov Number:  NCT01626079
Investigational Device Exemption (IDE) Number:  G120024/S021
CMS Approval Date: 02/05/2015

HHS is committed to making its websites and documents accessible to the widest possible audience, including individuals with disabilities. We are in the process of retroactively making some documents accessible. If you need assistance accessing an accessible version of this document, please reach out to the guidance@hhs.gov.

DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.